Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 0 · 0%High 2 · 40%

Aromatase inhibitors vs placebo

Overall breast cancer incidence · women with above‐average risk of developing breast cancer

Aromatase inhibitors leads to lower overall breast cancer incidence compared with placebo (high certainty).

1 finding from 1 review

Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
RR 0.47 [0.35, 0.63]
2 studies · 8424 participants
High

Aromatase inhibitors vs placebo

Severe toxicity · women with above‐average risk of developing breast cancer

Aromatase inhibitors leads to higher severe toxicity compared with placebo (high certainty).

1 finding from 1 review

Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
RR 1.18 [1.09, 1.28]
2 studies · 8352 participants
High

Aromatase inhibitors vs tamoxifen (indirect comparison)a

Overall breast cancer incidence · women with above‐average risk of developing breast cancer

Aromatase inhibitors may leads to lower overall breast cancer incidence compared with tamoxifen (indirect comparison)a (low certainty).

1 finding from 1 review

Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
RR 0.67 [0.46, 0.98]
5 studies · 31256 participants
Low

Exercise vs usual care

Adherence to aromatase inhibitors · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS)

It is very uncertain whether exercise therapies changes adherence to aromatase inhibitors compared with standard care (very low certainty).

1 finding from 1 review

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2020 · Cochrane Headline outcomes only
OR 2.43 [0.41, 14.63]
2 studies · 224 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Effect on discontinuation of aromatase inhibitors (AI) · women with early breast cancer

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 0.16 [0.01, 2.99]
1 study · 147 participants
Low